Figure 1
From: Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Hexa-Fc binds Fc-receptors with high avidity.
(a) Hexa-Fc binds to FcRL5 and FcγRIIb (CD32b). Binding of either heat-aggregated IgG1 (left panel) or hexa-Fc (right panel) to cells expressing FcRL5 (orange trace), FcγRIIb (blue trace), CD200R control (grey trace) or FcRL4 control (green trace). Binding to CD200R and FcRL4 (human IgA receptor) are included as two negative controls. Data are representative of duplicate experiments. (b) Improved binding of hexa-Fc when FcγRIIb and FcRL5 are simultaneously expressed on the surface of 293 cells. Binding of heat-aggregated IgG1 (left panel) or hexa-Fc (right panel) to FcRL5/FcγRIIb double transfectants (orange trace), FcRL5 single transfectants (red trace), FcRL4/FcγRIIb double transfectants (green trace) and FcγRIIb single transfectants (blue trace). CD200 transfected controls are omitted from the overlays for clarity. Cell surface expression of receptors was confirmed using FITC-conjugated anti-FLAG M2 mAb or anti-FcγRIIb antibodies (as shown in Figure S3). Data represent duplicate experiments.
